Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors

NCT06730347 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT06730347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06730347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors
Lead sponsor
MacroGenics
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2025
Completion date
December 31, 2027
Enrollment
80 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell adenocarcinoma of cervix, clear cell adenocarcinoma of fallopian tube, clear cell adenocarcinoma of ovary, clear cell adenocarcinoma of peritoneum, clear cell adenocarcinoma of uterus, clear cell adenocarcinoma of vagina, clear cell adenocarcinoma of vulva, endometrial cancer, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian cancer, platinum-resistant primary peritoneal carcinoma